Iliac Crest Bone Graft (ICBG) has historically been recognized as the gold standard in spinal arthrodesis procedures. However, its use is intrinsically associated with donor site complications, including chronic pain, paresthesia, risk of infection, and the limitation of available bone volume for harvesting. These disadvantages have motivated the exploration of biologically compatible and less invasive alternatives, such as Bone Marrow Aspirate (BMA). Although preliminary publications suggest favorable results, uncertainties persist regarding the actual effectiveness and safety of BMA in vertebral arthrodesis. Thus, the present study is a systematic review of the literature, conducted in accordance with the PRISMA Guidelines, whose primary objective was to evaluate the safety and clinical efficacy of BMA in spine arthrodesis procedures. The methodological quality of the identified Randomized Clinical Trials (RCTs) was assessed using the PEDro scale. The bibliographic search was performed by two independent reviewers in the Pubmed, Web Of Science, Scopus, and Embase databases, covering the period from 2005 to 2024. The descriptors “Bone Marrow Aspirate” OR “BMA” AND “Spine Fusion” OR “Spine Arthrodesis” were used, with the application of filters for “Randomized Controlled Trial,” “Meta-Analysis,” and “Systematic Reviews.” After screening and methodological evaluation, the final sample consisted of 14 studies. The consolidated data analysis demonstrated that BMA, notably when used in combination with synthetic grafts, presents satisfactory results concerning fusion rates, postoperative pain levels, and functional outcomes. These findings position BMA as a clinically viable alternative to ICBG. Level of Evidence II; Systematic Review.